RAS/RAF Pathway Mutation Profile (KRAS and NRAS reflex to BRAF)

CPT: 81275; 81276; 81311; 81479; 88381
Print Share

Test Details


  • BRAF
  • KRAS
  • NRAS


KRAS and NRAS are guanosine triphosphate (GTP)-binding proteins involved in downstream receptor signaling, which is critical for cell proliferation, survival and differentiation. Mutations in the KRAS and NRAS oncogene are frequently found in human cancers. They are common in pancreatic, colorectal, lung, bile duct, and thyroid cancer, as well as in melanomas. BRAF is an important member of the mitogen-activated protein kinase (MAPK) pathway that influences cell proliferation. Mutations in the BRAF oncogene are frequently found in human cancers, such as melanoma, colorectal cancer, lung cancer, ovarian cancer, thyroid cancer, and hairy cell leukemia. This assay detects KRAS and NRAS mutations in exons 2, 3, and 4, BRAF V600 mutations, allowing the determination of drug response.


This assay is able to detect 5% mutation in a background of wild-type DNA.

This test was developed, and its performance characteristics determined, by LabCorp. It has not been cleared or approved by the US Food and Drug Administration (FDA).


SNaPshot Multiplex PCR (primer extension-based method)

Specimen Requirements


Formalin-fixed, paraffin-embedded (FFPE) tissue block or slides


Formalin-fixed, paraffin-embedded (FFPE) tissue block or eight unstained slides and one matching H&E-stained slide at 5 μM

Minimum Volume

Four unstained slides at 5 μM and one matching H&E-stained slide


Formalin-fixed, paraffin-embedded (FFPE) tissue blocks or slides

Storage Instructions

Room temperature

Causes for Rejection

Tumor block containing insufficient tumor tissue; broken or stained slides

Clinical Information

Special Instructions

Provide a copy of the pathology report; the RAS/RAF test will be delayed if the pathology report is not received. Direct any questions regarding this test to customer service at 1-800-345-4363.


NCCN Clinical Practice Guidelines in Oncology: Colon Cancer v2. 2017.
NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer v2. 2017.

For Providers

Please login to order a test.


© 2018  Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.

CPT Statement/Profile Statement

The LOINC® codes are copyright © 1994-2018, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf